244 related articles for article (PubMed ID: 15864591)
1. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
Springate CM; Jackson JK; Gleave ME; Burt HM
Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
[TBL] [Abstract][Full Text] [Related]
2. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
[TBL] [Abstract][Full Text] [Related]
3. Clusterin antisense complexed with chitosan for controlled intratumoral delivery.
Springate CM; Jackson JK; Gleave ME; Burt HM
Int J Pharm; 2008 Feb; 350(1-2):53-64. PubMed ID: 17890029
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
6. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
[TBL] [Abstract][Full Text] [Related]
8. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
Lapidus RG; Dang W; Rosen DM; Gady AM; Zabelinka Y; O'Meally R; DeWeese TL; Denmeade SR
Prostate; 2004 Feb; 58(3):291-8. PubMed ID: 14743469
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
[TBL] [Abstract][Full Text] [Related]
11. Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice.
Obara K; Ishihara M; Ozeki Y; Ishizuka T; Hayashi T; Nakamura S; Saito Y; Yura H; Matsui T; Hattori H; Takase B; Ishihara M; Kikuchi M; Maehara T
J Control Release; 2005 Dec; 110(1):79-89. PubMed ID: 16289419
[TBL] [Abstract][Full Text] [Related]
12. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
Harper E; Dang W; Lapidus RG; Garver RI
Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
[TBL] [Abstract][Full Text] [Related]
13. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
El Hilali N; Rubio N; Blanco J
Clin Cancer Res; 2005 Feb; 11(3):1253-8. PubMed ID: 15709196
[TBL] [Abstract][Full Text] [Related]
14. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
15. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
Zellweger T; Chi K; Miyake H; Adomat H; Kiyama S; Skov K; Gleave ME
Clin Cancer Res; 2002 Oct; 8(10):3276-84. PubMed ID: 12374699
[TBL] [Abstract][Full Text] [Related]
16. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
[TBL] [Abstract][Full Text] [Related]
17. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.
Hayashi N; Koller E; Fazli L; Gleave ME
Prostate; 2008 Sep; 68(12):1283-95. PubMed ID: 18512732
[TBL] [Abstract][Full Text] [Related]
18. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
19. The characterization of novel polymeric paste formulations for intratumoral delivery.
Jackson JK; Zhang X; Llewellen S; Hunter WL; Burt HM
Int J Pharm; 2004 Feb; 270(1-2):185-98. PubMed ID: 14726134
[TBL] [Abstract][Full Text] [Related]
20. In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth.
Lee JY; Kim KS; Kang YM; Kim ES; Hwang SJ; Lee HB; Min BH; Kim JH; Kim MS
Int J Pharm; 2010 Jun; 392(1-2):51-6. PubMed ID: 20298770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
